• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch

    Simply Wall St·08/19/2026 19:18:35
    Listen to the news

    Abbott Laboratories (ABT) is drawing fresh investor interest after MiniMed began commercially shipping its app-controlled MiniMed Flex insulin pump in the U.S., which integrates Abbott’s Instinct continuous glucose sensor.

    See our latest analysis for Abbott Laboratories.

    Recent product news around the Instinct sensor and Abbott’s wider diabetes portfolio has coincided with stronger momentum, with a 30 day share price return of 11.92% and a 90 day share price return of 27.49%. This is even though the year to date share price return is down 9.27% and the 1 year total shareholder return is down 12.16%, while the 3 year total shareholder return of 14.07% points to a more balanced long term picture.

    If you are looking beyond Abbott Laboratories in health focused technology, this is a good moment to scan the market using the 42 healthcare AI stocks

    After Abbott Laboratories’ sharp rebound and fresh interest around MiniMed Flex and Lingo, the question now is whether the recent move has already captured most of the opportunity or if meaningful upside still lies ahead on valuation.

    Most Popular Narrative: 5.4% Undervalued

    Abbott Laboratories last closed at $112.68, compared with a most popular fair value estimate of $119.13 that applies a detailed long term cash flow and earnings framework.

    Analysts expect earnings to reach $9.5 billion (and earnings per share of $5.47) by about July 2029, up from $5.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $11.2 billion in earnings, and the most bearish expecting $6.4 billion.

    Read the complete narrative.

    Want to see what bridges that fair value gap for Abbott Laboratories? The narrative leans on steady revenue expansion, margin rebuild, and a richer earnings multiple. Curious which assumptions really move the model?

    Result: Fair Value of $119.13 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors in Abbott Laboratories still need to watch for ongoing pricing pressure in diagnostics, as well as any extended weakness from tariffs or foreign exchange that could weigh on margins.

    Find out about the key risks to this Abbott Laboratories narrative.

    Next Steps

    The mix of opportunity and concern around Abbott Laboratories is clear, but your own view matters most, especially with sentiment moving quickly. Take a closer look at the 3 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Abbott Laboratories?

    Do not stop with Abbott Laboratories. Use this moment to refresh your watchlist, compare opportunities, and line up your next moves with focused stock shortlists.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.